207 related articles for article (PubMed ID: 17785584)
1. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).
Guzman ML; Li X; Corbett CA; Rossi RM; Bushnell T; Liesveld JL; Hébert J; Young F; Jordan CT
Blood; 2007 Dec; 110(13):4436-44. PubMed ID: 17785584
[TBL] [Abstract][Full Text] [Related]
2. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity of hematopoietic progenitors to tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia.
Colovic M; Sefer D; Bogdanovic A; Suvajdzic N; Jankovic G; Atkinson HD; Milenkovic P
Cancer Lett; 2003 Jun; 195(2):153-9. PubMed ID: 12767523
[TBL] [Abstract][Full Text] [Related]
4. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
5. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
[TBL] [Abstract][Full Text] [Related]
6. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.
Nasim S; Guzman ML; Jordan CT; Crooks PA
Bioorg Med Chem Lett; 2011 Aug; 21(16):4879-83. PubMed ID: 21757349
[TBL] [Abstract][Full Text] [Related]
8. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
9. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
10. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Li L; Bhatia R
Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
[TBL] [Abstract][Full Text] [Related]
11. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
14. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
15. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
17. New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Lin H; Woolfson A; Jiang X
Methods Mol Biol; 2016; 1465():187-205. PubMed ID: 27581149
[TBL] [Abstract][Full Text] [Related]
18. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
19. Considerations for targeting malignant stem cells in leukemia.
Guzman ML; Jordan CT
Cancer Control; 2004; 11(2):97-104. PubMed ID: 15024346
[TBL] [Abstract][Full Text] [Related]
20. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
Wang Z; Chen CC; Chen W
Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
